RECENT PROGRESS IN OVARIAN CANCER THERAPY

Adeline Georgiana Staicu, Cristina Horescu, Stefania Tudorache
2021 Medico Oncology  
Ovarian cancer (OC) represents the leading cause of gynecological cancer deaths in women. It has a high variety of histological origins, molecular pathways and genetic mutations (BRCA1 and BRCA2 somatic/germinal mutations, Lynch genes, RADS1C, RADS1D etc.) that play a key role in treatment response and prognosis (for example, clear cell carcinoma is less responsive to standard therapy). An important percentage of patients (80%) are diagnosed with metastatic disease, due to the lack of specific
more » ... e lack of specific symptomatology and screening techniques leading to a dismal evolution. Standard treatment did not change drastically in decades consisting, nowadays, of cytoreductive surgery (debulking) and chemotherapy (a platinum-based agent, usually carboplatin and a taxane). Most patients experience complete response, but within a period of time, relapses occur and the cancerous cells may become platinum-resistant. This article depicts key clinical trials for many pharmacological agents including anti-angiogenesis drugs (bevacizumab, aflibercept, trebananib, pazopanib, sorafenib etc.), PARP-inhibitors (olaparib, niraparib), DNMT inhibitors (decitabine, azacytidine), various TKIs, DNA vaccines, oncolytic virus therapies and other agents.
doi:10.52701/monc.2020.v1i1.10 fatcat:iieaw4keubcv7d2vsz3muowfw4